Literature DB >> 10782390

Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis.

J Hedlund1, L O Hansson.   

Abstract

BACKGROUND: The diagnostic value of admission serum levels of procalcitonin (PCT) and C-reactive protein (CRP) as indicators of the etiology and prognosis was prospectively investigated. PATIENTS: 96 patients, 50-85 years of age, treated in the hospital for community-acquired pneumonia (CAP).
RESULTS: On admission, all patients had elevated CRP levels (> 10 mg/l), but only 60 patients (54%) had elevated PCT levels (> 0.1 microgram/l). The severity of disease measured by APACHE II score was strongly associated with admission levels of PCT (p = 0.006), but not with CRP. Eight of nine patients with pneumonia caused by atypical agents had PCT levels < 0.5 microgram/l compared with 6/27 patients with pneumonia caused by classic bacterial pathogens, mainly Streptococcus pneumoniae (p = 0.03). No such correlation between CRP levels and etiology was found.
CONCLUSION: Our data indicate that in patients admitted to the hospital with CAP, measurement of PCT gives information about the severity of the disease, and may aid the physician to differentiate typical bacterial etiology from atypical etiology, and thereby to choose appropriate initial antibiotic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10782390     DOI: 10.1007/s150100050049

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  43 in total

Review 1.  Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review.

Authors:  Victor van der Meer; Arie Knuistingh Neven; Peterhans J van den Broek; Willem J J Assendelft
Journal:  BMJ       Date:  2005-06-24

2.  Mannose-binding lectin does not act as an acute-phase reactant in adults with community-acquired pneumococcal pneumonia.

Authors:  M Perez-Castellano; M Peñaranda; A Payeras; J Milà; M Riera; J Vidal; F Pujalte; A Pareja; C Villalonga; N Matamoros
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

3.  Predicting the presence of bacterial pathogens in the airways of primary care patients with acute cough.

Authors:  Jolien Teepe; Berna D L Broekhuizen; Katherine Loens; Christine Lammens; Margareta Ieven; Herman Goossens; Paul Little; Chris C Butler; Samuel Coenen; Maciek Godycki-Cwirko; Theo J M Verheij
Journal:  CMAJ       Date:  2016-10-24       Impact factor: 8.262

4.  Biomarkers for community-acquired pneumonia in the emergency department.

Authors:  Todd A Florin; Lilliam Ambroggio
Journal:  Curr Infect Dis Rep       Date:  2014-12       Impact factor: 3.725

5.  Bacteraemia prediction in emergency medical admissions: role of C reactive protein.

Authors:  D H Wyllie; I C J W Bowler; T E A Peto
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

6.  Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia.

Authors:  Matjaz Jereb; Tadeja Kotar
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

7.  Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ.

Authors:  Stefan Krüger; Santiago Ewig; Jana Papassotiriou; Jan Kunde; Reinhard Marre; Heike von Baum; Norbert Suttor; Tobias Welte
Journal:  Respir Res       Date:  2009-07-12

Review 8.  Improving outcomes of elderly patients with community-acquired pneumonia.

Authors:  Félix Gutiérrez; Mar Masiá
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  Biomarkers: a definite plus in pneumonia.

Authors:  Hanssa Summah; Jie-Ming Qu
Journal:  Mediators Inflamm       Date:  2009       Impact factor: 4.711

10.  Role of C-reactive protein and procalcitonin in differentiation of tuberculosis from bacterial community acquired pneumonia.

Authors:  Young Ae Kang; Sung-Youn Kwon; Ho Il Yoon; Jae Ho Lee; Choon-Taek Lee
Journal:  Korean J Intern Med       Date:  2009-11-27       Impact factor: 2.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.